登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C19H26O3
化学文摘社编号:
分子量:
302.41
EC Number:
208-116-5
UNSPSC Code:
12352103
PubChem Substance ID:
Beilstein/REAXYS Number:
2567249
MDL number:
Assay:
≥90% (HPLC)
Form:
crystals
InChI
1S/C19H26O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10,14-16,20H,2-9,11H2,1H3/t14-,15-,16-,18-,19+/m0/s1
InChI key
XGUHPTGEXRHMQQ-BGJMDTOESA-N
SMILES string
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34CO)[C@@H]1CCC2=O
assay
≥90% (HPLC)
form
crystals
optical activity
[α]/D +190±5°, c = 1 in chloroform
storage temp.
−20°C
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
H Sekihara et al.
Clinical endocrinology, 39(5), 557-560 (1993-11-01)
We have reported that 19-hydroxyandrostenedione (19-OH-A-dione) functions as an amplifier of the sodium-retaining and hypertensive action of aldosterone. We therefore measured 19-hydroxyandrostenedione in hypertensive patients. We studied 53 normal male control subjects and 63 male patients with essential hypertension (48
H Morita et al.
Endocrine journal, 40(1), 89-97 (1993-02-01)
The present study was performed to clarify changes in plasma levels of 19-hydroxyandrostenedione (19-OH-AD), an amplifier of aldosterone and a possible hypertensinogenic steroid, during several tests for the renin-angiotensin system in 20 patients with aldosterone-producing adenoma (APA) and to determine
S Ohnishi et al.
Steroids, 55(1), 5-9 (1990-01-01)
19-Hydroxyandrostenedione (19-OHA), highly labeled with deuterium at position 7, was synthesized from unlabeled androstenediol diacetate. The deuterium labels were introduced into the 7-keto compound with dichloroaluminum deuteride to obtain [7-2H2]androstenediol. The labeled androstenediol diacetate was converted to the labeled 19-OHA
M Minato et al.
Nihon Naibunpi Gakkai zasshi, 66(1), 29-41 (1990-01-20)
In order to evaluate the hypertensinogenic action of 19-hydroxyandrostenedione (19-OH-AD), which has been reported to be an amplifier of mineralocorticoid, the changes in several humoral factors were observed in 19-OH-AD treated rats as compared to those in DOCA hypertensive rats.
K Higuchi et al.
Endocrinologia japonica, 36(6), 881-885 (1989-12-01)
The steroid, 19-hydroxyandrost-4-ene-3, 17-dione (19-hydroxyandrostene-dione, 19-OH-A-dione) has been known to enhance the mineralocorticoid action of aldosterone. To investigate the age-related change in the plasma 19-OH-A-dione concentration, plasma 19-OH-A-dione, androst-4-ene-3, 17-dione (A-dione), aldosterone and cortisol of 38 non-hypertensive healthy subjects (18
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持